• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Williams Thomas Charles

    4/25/25 4:01:45 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Williams Thomas Charles

    (Last) (First) (Middle)
    3030 NORTH ROCKY POINT DRIVE
    SUITE 420

    (Street)
    TAMPA FL 33607

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    UPEXI, INC. [ UPXI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/17/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Options to buy common stock $3.46 01/17/2025 A 25,000 04/17/2025 01/17/2035 Common Stock 25,000 $0 25,000 D
    Explanation of Responses:
    Remarks:
    /s/ Thomas Williams 04/24/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $UPXI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

      6/16/25 7:42:40 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Rudick Brian Benjamin claimed ownership of 438,597 shares (SEC Form 3)

      3 - UPEXI, INC. (0001775194) (Issuer)

      6/3/25 6:04:17 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Williams Thomas Charles

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:45 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    SEC Filings

    See more
    • Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      6/26/25 5:00:22 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Upexi Inc.

      EFFECT - UPEXI, INC. (0001775194) (Filer)

      6/24/25 12:15:14 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B3 filed by Upexi Inc.

      424B3 - UPEXI, INC. (0001775194) (Filer)

      6/23/25 5:00:28 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Upexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening Bell

      TAMPA, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its intention to tokenize its SEC-registered shares using Opening Bell, an on-chain issuance platform from financial technology firm Superstate. Opening Bell enables companies to tokenize public equity via blockchain infrastructure, making shares tradable on-chain. This announcement expands upon Upexi's existing Nasdaq listing and upon official listing may introduce key investor benefits, including: 24/7 trading and

      6/26/25 8:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Nakamoto Holdings to Participate in ICR Conference Spotlight Series

      Nakamoto Holdings Inc. ("Nakamoto"), a Bitcoin-native holding that has entered into a definitive merger agreement with KindlyMD, Inc. (NASDAQ:NAKA) ("KindlyMD"), is pleased to share that David Bailey, Chief Executive Officer, will participate in an ICR Conference Spotlight Series webinar taking place on Friday, June 20, 2025 at 11am ET. The webinar, titled "HODL On Tight: Examining The Rise of Public Market Crypto Balance Sheet Strategies", will examine the evolution of crypto balance sheet strategies and the strategic rationale and benefits driving the proliferation of these public market companies. David will be joined by executives from Clear Street Investment Banking, Upexi, Inc. (NAS

      6/17/25 4:05:00 PM ET
      $NAKA
      $UPXI
      Medical/Nursing Services
      Health Care
      Medicinal Chemicals and Botanical Products
    • Upexi's Chief Strategy Officer to Present at The ICR Conference Spotlight Series on June 20th

      TAMPA, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced that Brian Rudick, CFA, Chief Strategy Officer (CSO), will present on a panel at the ICR Conference Spotlight Series on Friday, June 20, 2025, at 11:00 a.m. ET. Along with Upexi's CSO Brian Rudick, this virtual panel will feature industry leaders including David Bailey, Founder and CEO of Nakamoto, Leah Wald, President & Chief Executive Officer at Sol Strategies, Inc., and John D'Agostini, Co-Head of Investment Banking at Cl

      6/17/25 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Financials

    Live finance-specific insights

    See more
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Reports Fiscal Second Quarter 2024 Financial Results

      TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

      2/14/24 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

      2/12/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      5/31/23 7:05:10 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:37:37 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

      SC 13G/A - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:36:56 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care